Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0HM6Q
|
|||
Drug Name |
PMID27539678-Compound-13
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
AJINOMOTO CO., INC
|
|||
Structure |
Download2D MOL |
|||
Formula |
C26H30N2O
|
|||
Canonical SMILES |
C1CCC(=CC1)C2=CC=CC(=C2)C3=CC4=C(C=C3)NC(=C4)CN5CCCC5CO
|
|||
InChI |
1S/C26H30N2O/c29-18-25-10-5-13-28(25)17-24-16-23-15-22(11-12-26(23)27-24)21-9-4-8-20(14-21)19-6-2-1-3-7-19/h4,6,8-9,11-12,14-16,25,27,29H,1-3,5,7,10,13,17-18H2/t25-/m1/s1
|
|||
InChIKey |
VGAFMTJLEJHSLL-RUZDIDTESA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Sphingosine kinase 1 (SPHK1) | Target Info | Inhibitor | [1] |
Target's Patent Info | Sphingosine kinase 1 (SPHK1) | Target's Patent Info | [1] | |
BioCyc | Sphingosine and sphingosine-1-phosphate metabolism | |||
KEGG Pathway | Sphingolipid metabolism | |||
Metabolic pathways | ||||
Calcium signaling pathway | ||||
Sphingolipid signaling pathway | ||||
VEGF signaling pathway | ||||
Fc gamma R-mediated phagocytosis | ||||
Tuberculosis | ||||
NetPath Pathway | TCR Signaling Pathway | |||
TNFalpha Signaling Pathway | ||||
Panther Pathway | Angiogenesis | |||
VEGF signaling pathway | ||||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
Beta3 integrin cell surface interactions | ||||
S1P1 pathway | ||||
Sphingosine 1-phosphate (S1P) pathway | ||||
PDGFR-beta signaling pathway | ||||
Reactome | Sphingolipid de novo biosynthesis | |||
VEGFR2 mediated cell proliferation | ||||
WikiPathways | Signal Transduction of S1P Receptor | |||
Protein folding | ||||
Sphingolipid Metabolism |
References | Top | |||
---|---|---|---|---|
REF 1 | Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.